Antimicrobial Susceptibility Trends among Staphylococcus aureus Isolates from U.S. Hospitals: Results from 7 Years of the Ceftaroline (AWARE) Surveillance Program, 2010 to 2016 | Zendy

Hélio S. Sader | Zendy; Rodrigo E. Mendes | Zendy; Jennifer M Streit | Zendy; Robert K. Flamm | Zendy

Open Access

Antimicrobial Susceptibility Trends among Staphylococcus aureus Isolates from U.S. Hospitals: Results from 7 Years of the Ceftaroline (AWARE) Surveillance Program, 2010 to 2016

Author(s) -

Hélio S. Sader,

Rodrigo E. Mendes,

Jennifer M Streit,

Robert K. Flamm

Publication year - 2017

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01043-17

Subject(s) - broth microdilution , staphylococcus aureus , clindamycin , medicine , microbiology and biotechnology , erythromycin , levofloxacin , trimethoprim , antimicrobial , methicillin resistant staphylococcus aureus , antibiotics , cephalosporin , biology , minimum inhibitory concentration , bacteria , genetics

We evaluated trends inStaphylococcus aureus antimicrobial susceptibility in U.S. hospitals in the 2010–2016 period. A total of 21,056 clinical isolates from 42 medical centers were tested for susceptibility by broth microdilution methods. Methicillin-resistantS. aureus (MRSA) rates decreased from 50.0% (in 2010) to 42.2% (in 2016). Susceptibility to erythromycin, levofloxacin, and clindamycin increased slightly, whereas susceptibility to ceftaroline, trimethoprim-sulfamethoxazole, and tetracycline remained stable. Ceftaroline retained potent activity against methicillin-susceptibleS. aureus (MSSA) and MRSA (97.2% susceptible) with no marked variations.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research